Notably, the efficacy of SR-A3 in Myc-driven tumors holds significant clinical relevance, as Myc-dependent cancers typically rely on hyperactivated protein synthesis, yet direct Myc-targeting therapies remain elusive. This evidence concerns the gene MYC and cancer.